However, among the comparatively small matched cohort of individuals with baseline HF (n = 1937 for DPP-4 inhibitors; n = 1937 for GLP-1 agonists), we observed no evidence of differential HF hospitalization risk (HR, 0.90; 95% CI 0.74, 1.07). The gene discussed is GCG; the disease is hydrops fetalis.